|
Sanofi/Genzyme: modest efficacy sees Aubagio
compete on price Equities.com Sanofi/Genzyme: modest efficacy sees Aubagio compete on price. The FDA has approved Aubagio, a once-daily, oral treatment for relapsing multiple sclerosis. Comtex News Network. Sep 14, 2012 (Datamonitor via COMTEX) — Following the announcement … See all stories on this topic » |
|
FDA Approves Genzyme’s AUBAGIO … –
Yahoo! Finance From Yahoo! Finance: Genzyme, a Sanofi company , announced today that the U.S. Food and Drug Administration has approved AUBAGIO® as a new … finance.yahoo.com/…/fda-approves-genzyme-aubagio-teriflun…
Recent posts of interest:
13 Sep 2012
MSers receiving teriflunomide 14 mg had a statistically significant reduction in annualised relapse rate and risk of sustained accumulation of disability. This double-blind, multi-center trial enrolled 1,169 MSers and compared .
13 Sep 2012
“For those of you who want more information I have uploaded Teriflunomide’s highlights of prescribing information for you to review and download. I am expecting a lot of questions.” CoI: multiple. Posted by Gavin Giovannoni …
26 Jun 2012
Background:The Teriflunomide Multiple Sclerosis Oral (TEMSO) trial, a randomized, double-blind, placebo-controlled phase III study, demonstrated that teriflunomide significantly reduced annualized relapse rate (ARR), …
07 Jun 2012
MSers receiving teriflunomide 14 mg had a statistically significant reduction in annualised relapse rate and risk of sustained accumulation of disability. This double-blind, multi-center ial enrolled 1,169 MSers and compared …
|